Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps

Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps

Spinal muscular atrophy (SMA) is a recessive disorder caused by a mutation in the survival motor neuron 1 gene (SMN1); it affects 1 in 11 000 newborn infants. The most severe and most common form, type 1 SMA, is associated with early mortality in most cases and severe disability in survivors. Nusine...

Bibliografski detalji
Glavni autori:	Gidaro, T, Servais, L
Format:	Journal article
Jezik:	English
Izdano:	Wiley 2018

Slični predmeti

Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
od: Aragon-Gawinska, K, i dr.
Izdano: (2019)

Nusinersen and spinal muscular atrophies: Where are we in 2020?
od: Satish V Khadilkar, i dr.
Izdano: (2020-01-01)

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
od: Finkel, RS, i dr.
Izdano: (2017)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
od: Tommaso Nuzzo, i dr.
Izdano: (2023-02-01)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
od: Benjamin Stolte, i dr.
Izdano: (2018-10-01)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
od: Maren Freigang, i dr.
Izdano: (2021-07-01)

Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study
od: Aragon-Gawinska, K, i dr.
Izdano: (2018)

Nusinersen versus sham control in later-onset spinal muscular atrophy
od: Mercuri, E, i dr.
Izdano: (2018)

Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy
od: Qiang Zhang, i dr.
Izdano: (2024-10-01)

History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
od: Jiaying Qiu, i dr.
Izdano: (2022-08-01)

Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome
od: Andrada Mirea, i dr.
Izdano: (2022-06-01)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
od: Maria Carmela Pera, i dr.
Izdano: (2021-08-01)

Nusinersen in spinal muscular atrophy: Respiratory outcomes at tertiary care centers
od: Fahad Alsohime, i dr.
Izdano: (2020-01-01)

Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment
od: Yiğithan Güzin, i dr.
Izdano: (2024-11-01)

Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China
od: Dan Li, i dr.
Izdano: (2024-07-01)

Quality of Life Assessment in Romanian Patients with Spinal Muscular Atrophy Undergoing Nusinersen Treatment
od: Bogdana Cavaloiu, i dr.
Izdano: (2024-08-01)

Treatment with nusinersen in a girl with spinal muscular atrophy type 1 - Case report
od: Tanja Loboda, i dr.
Izdano: (2020-07-01)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
od: Isabell Cordts, i dr.
Izdano: (2020-01-01)

New treatments in spinal muscular atrophy: an overview of currently available data
od: Ramdas, S, i dr.
Izdano: (2020)

Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
od: Hüseyin Bahadır Şenol, i dr.
Izdano: (2025-01-01)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
od: Alma Osmanovic, i dr.
Izdano: (2021-03-01)

Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
od: Francesco Errico, i dr.
Izdano: (2022-10-01)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
od: Praveen Thokala, i dr.
Izdano: (2020-10-01)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
od: Bakri Elsheikh, i dr.
Izdano: (2021-04-01)

Exploring the Influence of Concurrent Nutritional Therapy on Children with Spinal Muscular Atrophy Receiving Nusinersen Treatment
od: Eymen Pinar, i dr.
Izdano: (2024-07-01)

Nusinersen Treatment for Spinal Muscular Atrophy: Retrospective Multicenter Study of Pediatric and Adult Patients in Kuwait
od: Asma AlTawari, i dr.
Izdano: (2024-06-01)

Clinical and Electrophysiological Changes in Pediatric Spinal Muscular Atrophy after 2 Years of Nusinersen Treatment
od: Mihaela Axente, i dr.
Izdano: (2022-09-01)

Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
od: Sayo Nakao, i dr.
Izdano: (2020-04-01)

Real-world analysis of the efficacy and safety of nusinersen in pediatric patients with spinal muscular atrophy
od: Wenjing Li, i dr.
Izdano: (2025-02-01)

Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis
od: Tim Hagenacker, i dr.
Izdano: (2024-09-01)

Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database
od: Ying Jiang, i dr.
Izdano: (2024-07-01)

Safety analysis of laboratory parameters in paediatric patients with spinal muscular atrophy treated with nusinersen
od: Xiaomei Zhu, i dr.
Izdano: (2024-07-01)

Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
od: Tristan Weaver, i dr.
Izdano: (2021-09-01)

Effects of nusinersen on motor function in children with spinal muscular atrophy: a retrospective study
od: Yuyi Chen, i dr.
Izdano: (2024-07-01)

Quality of Life Outcomes According to Differential Nusinersen Exposure in Pediatric Spinal Muscular Atrophy
od: Meaghann S. Weaver, i dr.
Izdano: (2021-07-01)

Nusinersen injections in adults and children with spinal muscular atrophy: a single-center experience
od: Can Özütemiz, i dr.
Izdano: (2020-11-01)

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
od: Marika Pane, i dr.
Izdano: (2022-03-01)

Experience of Nusinersen in children with proximal spinal muscular atrophy 5q in Moscow region
od: M. V. Panteleeva
Izdano: (2022-12-01)

Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
od: Dangouloff T, i dr.
Izdano: (2019-10-01)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
od: Konstantinos Biliouris, i dr.
Izdano: (2018-09-01)